Patient Representative at Drugs for Neglected Diseases initiative (DNDi)

  Drugs for Neglected Diseases initiative (DNDi) is an independent, not-for-profit drug development initiative established in 2003 by five publicly-funded research organizations - Malaysian Ministry of Health, Kenya Medical Research Institute, Indian Council of Medical Research, Oswaldo Cruz Foundation Brazil, and the Institut Pasteur - as well as an international humanitarian organization, Médecins Sans Frontières. The UNICEF/UNDP/World Bank/WHO’s Special Programme for Research and Training in Tropical Diseases (TDR) is a permanent observer. With a robust portfolio, DNDi aims to develop new, improved, and field-relevant drugs for neglected diseases, including leishmaniasis, human African trypanosomiasis (sleeping sickness), Chagas disease, malaria, filarial diseases, paediatric HIV, mycetoma, and hepatitis C that afflict the poorest populations of the world.

Board members:

• regularly attend, and actively participate in, Board meetings and related meetings;
• consider volunteering for and willingly accepting assignments, such as Board subcommittee work, and complete them thoroughly and on time;
• stay informed about the evolution in the field of global health, prepare themselves well
• for meetings, and review and comment on minutes and reports. 

ROLE OF PATIENT REPRESENTATIVE BOARD MEMBER

• The Patient Representative Board members role ensures DNDi’s work remains aligned with the true needs of those it serves, and improves the relevance and impact of its R&D efforts.
• The Patient Representative Board member integrates the patient’s voice intDNDi’s governance processes tensure the Board’s decisions are informed by patient’s needs and priorities.
• The Patient Representative Board member strengthens Board discussions by contributing with their understanding of, and advocating for:
• patient experiences and perspectives (tensure decisions consider the impact on patient health and quality of life); and a patient-centered viewpoint for ethical considerations and regulatory frameworks (especially concerning clinical trials, access ttreatments, informed consent, the creation and active participation of community advisory committees).

The Patient Representative Board member:

• fosters relationships with communities (including patient groups) tensure DNDi
• maintains strong, mutually beneficial relationships with these groups;
• advocates for the formation of patient groups where they dnot exist; and encourages dialogue and feedback between DNDi, patients, and communities, including interfacing with DNDi’s Regional Community Advisory Committees.

Interested persons are invited to send in a CV, letter of interest, and the nomination form to afolkes@dndi.org